Modelling the natural history of primary progressive multiple sclerosis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 1, 2015, Pages 13-19

  Harding, Katharine E ^a,b   Wardle, Mark ^b   Moore, Perry ^a,c   Tomassini, Valentina ^a,b   Pickersgill, Trevor ^b   Ben Shlomo, Yoav ^d   Robertson, Neil P ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d MRC Centre for Causal Analyses in Translational Epidemiology (CAiTE)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; ARTICLE; CEREBELLUM DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; POPULATION MODEL; PREDICTION; PROGNOSIS; SURVIVAL TIME; AGED; BIOLOGICAL MODEL; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; RECURRENT DISEASE; SURVIVAL; UNITED KINGDOM;

AGE OF ONSET; AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENCE; SURVIVAL ANALYSIS; WALES;

EID: 84919781097     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-307791     Document Type: Article

References (40)

1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 1996;46:907-11.
2. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. a serial MRI study. Brain 1996;119:2009-19.
3. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
4. IMSGC. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476:214-9.
5. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-89.
6. Andersson PB, Waubant E, Gee L, et al. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol 1999;56:1138-42.
7. Minderhoud JM, van der Hoeven JH, Prange AJ. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 1988;78:10-15.
8. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-34.
9. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. the clinical features and natural history of primary progressive multiple sclerosis. Brain 1999;122:625-39.
10. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606-16.
11. Debouverie M, Louis S, Pittion-Vouyovitch S, et al. Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol 2007;254:1370-5.
12. Koch M, Kingwell E, Rieckmann P, et al. The natural history of primary progressive multiple sclerosis. Neurology 2009;73:1996-2002.
13. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74:2004-15.
14. Rice CM, Cottrell D, Wilkins A, et al. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry 2013;84:1100-6.
15. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
16. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504.
17. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 2006;354:899-910.
18. La Mantia L, Vacchi L, Di Pietrantonj C, et al. Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev 2012;1:CD005181.
19. Anderson VM, Fox NC, Miller DH. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 2006;23:605-18.
20. Niklas A, Sebraoui H, Hess E, et al. Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Mult Scler 2009;15:68-74.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
22. Welsh Assembly Government. Mid-yr Estimates of the Population. 2010. http://wales.gov.uk/topics/statistics/headlines/population2011/110630/?lang=en (accessed 20 Aug 2012).
23. Poser CM, Paty DW, Scheinberg L, et al . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
24. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
25. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58:840-6.
26. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
27. Ingram G, Colley E, Ben-Shlomo Y, et al. Validity of patient-derived disability and clinical data in multiple sclerosis. Mult Scler 2010;16:472-9.
28. Swingler RJ, Compston DA. The prevalence of multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry 1988;51:1520-4.
29. Hennessy A, Swingler RJ, Compston DA. The incidence and mortality of multiple sclerosis in south east Wales. J Neurol Neurosurg Psychiatry 1989;52:1085-9.
30. Hennessey A, Robertson NP, Swingler R, et al. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 1999;246:1027-32.
31. Hirst C, Ingram G, Pickersgill T, et al. Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry 2009;80:386-91.
32. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology 2006;67:954-9.
33. Wolinsky JS, Narayana PA, O' Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
34. Coles AJ, Compston DA, Selmaj KW, CAMMS223 Trial Investigators, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
35. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
36. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303.
37. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. 2011. http://www.r-project.org (accessed 31 Dec 2013).
38. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1919-23.
39. Cottrell DA, Kremenchutzky M, Rice GP, et al . The natural history of multiple sclerosis: a geographically based study. 6. applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 1999;122:641-7.
40. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurology 2013;12:857-65.